Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gilles CREHANGE, MD, PhD
Institut Curie
Study Chair - Pierre BLANCHARD, MD, PhD
Gustave Roussy, Cancer Campus, Grand Paris
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Clinique Pasteur Lanroze - Brest
Brest, France
Recruiting - Centre Georges Francois Leclerc
Dijon, France
Recruiting - Groupe Hospitalier Paris Saint-Joseph
Paris, France
Recruiting - Chu Saint-Etienne
Saint-Etienne, France
Recruiting - Gustave Roussy, Cancer Campus, Grand Paris
Villejuif, France
Recruiting
- Chu Martinique
Fort-de-France, Martinique
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Apr 2025
- Primary completion
- 31 Oct 2033
- Completion
- 31 Oct 2045
- Last update posted
- 26 Jun 2025
- Registered enrollment
- 700
- Registry id
- NCT06625970
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.